First-line treatment with nivolumab plus ipilimumab provides durable long-term survival benefit for patients with advanced NSCLC, regardless of tumor PD-L1 expression and histology, as observed in CheckMate 227 [1, 15]. This evidence concerns the gene CD274 and neoplasm.